| 2026-09-11 17:24 |
8-K |
["5.02", "9.01"] |
officer change |
0.15
|
Director resignation with no disagreement stated; insufficient M&A indicator without additional context. |
SEC · detail |
| 2026-09-09 09:01 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine 8-K announcing R&D Day webinar on relapsing MS program; no M&A signals. |
SEC · detail |
| 2026-08-11 07:05 |
8-K |
["2.02", "5.02"] |
officer change |
0.35
|
CEO departure and CFO-background director appointment; weak M&A signal absent explicit transaction language. |
SEC · detail |
| 2026-07-14 08:01 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine investor presentation update with forward-looking statements; no M&A signals. |
SEC · detail |
| 2026-07-06 16:22 |
8-K |
["5.02"] |
officer change |
0.15
|
Routine board departure and CEO appointment; no M&A implications indicated. |
SEC · detail |
| 2026-06-29 16:05 |
8-K |
["5.02", "5.07", "9.01"] |
other |
0.05
|
Routine annual shareholder meeting with equity plan amendment; no M&A indicators present. |
SEC · detail |
| 2026-05-28 07:01 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine clinical trial data presentation disclosure; no M&A signals detected. |
SEC · detail |
| 2026-05-27 07:00 |
8-K |
["5.02"] |
officer change |
0.52
|
New CEO appointment from Roche/Genentech with enhanced Change of Control severance provisions suggests M&A readiness. |
SEC · detail |
| 2026-05-19 07:00 |
8-K |
["5.02", "7.01", "9.01"] |
officer change |
0.52
|
Appointment of experienced M&A-linked chair (Cubist/Merck $9.5B exit) suggests potential strategic review, but lacks explicit M&A language. |
SEC · detail |
| 2026-05-13 07:01 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings announcement with corporate update; no M&A signals detected. |
SEC · detail |
| 2026-04-28 07:00 |
8-K |
["5.02"] |
officer change |
0.25
|
Chief Medical Officer appointment with change-of-control severance provisions; standard officer hire with M&A-adjacent protections. |
SEC · detail |